Bpifrance is expected to participate as a minority shareholder with a stake of about 2% stake in Opella, with Sanofi remaining a significant shareholder.

The terms of the transaction remain unchanged from those previously announced and closing is expected in the second quarter of 2025 at the earliest.

This transaction remains subject to obtaining customary regulatory approvals from the competent authorities.